Bourgeon Capital Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-410
| Closed | -$41.4K | – | 282 |
|
|
2023
Q4 | $41.4K | Buy |
410
+24
| +6% | +$2.32K | 0.01% | 156 |
|
|
2023
Q3 | $39.3K | Buy |
386
+36
| +10% | +$3.65K | 0.01% | 154 |
|
|
2023
Q2 | $35.3K | Hold |
350
| – | – | 0.01% | 174 |
|
|
2023
Q1 | $32.2K | Hold |
350
| – | – | 0.01% | 168 |
|
|
2022
Q4 | $31.8K | Hold |
350
| – | – | 0.01% | 174 |
|
|
2022
Q3 | $27K | Hold |
350
| – | – | 0.01% | 163 |
|
|
2022
Q2 | $30K | Hold |
350
| – | – | 0.01% | 161 |
|
|
2022
Q1 | $31K | Hold |
350
| – | – | 0.01% | 168 |
|
|
2021
Q4 | $31K | Sell |
350
-450
| -56% | -$37.4K | 0.01% | 169 |
|
|
2021
Q3 | $65K | Hold |
800
| – | – | 0.01% | 152 |
|
|
2021
Q2 | $73K | Hold |
800
| – | – | 0.02% | 147 |
|
|
2021
Q1 | $68K | Sell |
800
-58,966
| -99% | -$5.29M | 0.02% | 149 |
|
|
2020
Q4 | $5.64M | Sell |
59,766
-1,102
| -2% | -$96.3K | 1.39% | 31 |
|
|
2020
Q3 | $5.29M | Buy |
60,868
+642
| +1% | +$55.6K | 1.6% | 28 |
|
|
2020
Q2 | $5.26M | Buy |
60,226
+4,030
| +7% | +$348K | 1.87% | 24 |
|
|
2020
Q1 | $4.63M | Buy |
56,196
+875
| +2% | +$78.1K | 2.4% | 15 |
|
|
2019
Q4 | $5.24M | Sell |
55,321
-1,090
| -2% | -$97.8K | 2.47% | 16 |
|
|
2019
Q3 | $4.9M | Buy |
56,411
+405
| +0.7% | +$36.4K | 2.66% | 14 |
|
|
2019
Q2 | $5.11M | Sell |
56,006
-6,664
| -11% | -$564K | 2.97% | 14 |
|
|
2019
Q1 | $5.4M | Sell |
62,670
-265
| -0.4% | -$21.3K | 3.17% | 12 |
|
|
2018
Q4 | $4.84M | Sell |
62,935
-14,586
| -19% | -$1.14M | 3.17% | 11 |
|
|
2018
Q3 | $5.99M | Buy |
77,521
+3,895
| +5% | +$288K | 3.09% | 11 |
|
|
2018
Q2 | $4.98M | Sell |
73,626
-1,004
| -1% | -$69.3K | 2.68% | 20 |
|
|
2018
Q1 | $5.41M | Buy |
74,630
+2,929
| +4% | +$223K | 2.96% | 13 |
|
|
2017
Q4 | $5.39M | Sell |
71,701
-960
| -1% | -$72.4K | 2.95% | 12 |
|
|
2017
Q3 | $5.59M | Buy |
72,661
+21
| +0% | +$1.59K | 3.29% | 10 |
|
|
2017
Q2 | $5.43M | Buy |
72,640
+16,254
| +29% | +$1.15M | 3.4% | 9 |
|
|
2017
Q1 | $3.75M | Buy |
56,386
+391
| +0.7% | +$26.1K | 2.34% | 16 |
|
|
2016
Q4 | $3.65M | Sell |
55,995
-1,312
| -2% | -$85.1K | 2.3% | 19 |
|
|
2016
Q3 | $4.05M | Sell |
57,307
-3,906
| -6% | -$285K | 2.6% | 17 |
|
|
2016
Q2 | $4.53M | Buy |
61,213
+3,214
| +6% | +$222K | 2.94% | 9 |
|
|
2016
Q1 | $3.77M | Sell |
57,999
-1,422
| -2% | -$96.7K | 2.51% | 13 |
|
|
2015
Q4 | $4.58M | Buy |
59,421
+10,518
| +22% | +$836K | 2.94% | 8 |
|
|
2015
Q3 | $4.03M | Sell |
48,903
-614
| -1% | -$54.6K | 2.81% | 9 |
|
|
2015
Q2 | $4.36M | Buy |
49,517
+223
| +0.5% | +$20.5K | 2.64% | 5 |
|
|
2015
Q1 | $4.36M | Sell |
49,294
-770
| -2% | -$68.3K | 2.67% | 6 |
|
|
2014
Q4 | $4.16M | Sell |
50,064
-12,611
| -20% | -$1.05M | 2.54% | 6 |
|
|
2014
Q3 | $5.29M | Buy |
62,675
+62
| +0.1% | +$5.02K | 3.08% | 3 |
|
|
2014
Q2 | $5.08M | Buy |
62,613
+7,098
| +13% | +$558K | 2.77% | 6 |
|
|
2014
Q1 | $4.23M | Sell |
55,515
-168
| -0.3% | -$12.2K | 2.66% | 7 |
|
|
2013
Q4 | $4.01M | Buy |
55,683
+307
| +0.6% | +$21.3K | 2.58% | 8 |
|
|
2013
Q3 | $3.81M | Buy |
55,376
+1,451
| +3% | +$96K | 2.57% | 7 |
|
|
2013
Q2 | $3.42M | Buy |
+53,925
| New | +$3.51M | 2.43% | 7 |
|
Other funds holding NVS
Bourgeon Capital Management's NVS Position: Q1 2024 in Review
Bourgeon Capital Management sold out of Novartis (NVS) in Q1 2024, closing a stake of 410 shares — an estimated $41.4K sold.
Bourgeon Capital Management first reported a position in NVS in Q2 2013 and held it in 43 quarters. The position peaked at $5.99M in Q3 2018. 1,254 funds tracked by Wall St. Rank hold NVS as of Q1 2024.
- Bourgeon Capital Management reported no remaining Novartis position as of Q1 2024 after selling out during the quarter.
- Bourgeon Capital Management sold 410 Novartis shares in Q1 2024, an estimated $41.4K.
- Bourgeon Capital Management first reported a position in Novartis in Q2 2013 and held it in 43 quarters.
- Bourgeon Capital Management's Novartis position peaked at $5.99M in Q3 2018.
- 1,254 funds tracked by Wall St. Rank held Novartis as of Q1 2024.
Based on Bourgeon Capital Management's 13F filing for Q1 2024, filed 19 Apr 2024.